SlideShare uma empresa Scribd logo
1 de 19
Baixar para ler offline
1
1Q11 Earnings Release
           May, 11th, 2011




                             2
Highlights in the Period


• In May 2011, Profarma celebrates its 50th Anniversary. The Company’s result-oriented culture, coupled with a long-term
vision based on everyday practical and objective initiatives, will be crucial to continue consolidating its position in the
pharmaceutical distribution industry in Brazil;

• A rise of 1.7% in the consolidated gross revenues when compared to the same period in the previous year, totaling R$
778.8 million;

• Highlight for the Health and Beauty category, which showed growing sales for the fifth consecutive quarter, and an
outstanding increase of 78.0% in comparison with the same period in the previous year;

• A drop of 31.4% in the EPM (Errors Per Million of shipped units), which changed from 210.0 recorded in the 1Q10 to 144.0
in the 1Q11;

• The annual prices increase occurred in March 31, 2011 was 4.6%, in line with the inflation accrued over the last 12
months. This is the second higher price increase over the last five years.




                                                                                                                              3   3
Gross Revenues Evolution
                (R$ Million)




                  832.3
766.0                              778.8




1Q10              4Q10             1Q11




                                           4   4
Gross Revenues Breakdown


(R$ Million)                    1Q11    1Q10    Chg. %   4Q10    Chg. %

Branded                         507.1   511.7   -0.9%    554.6   -8.6%
Generic                          54.5    51.6   5.6%      59.6   -8.7%
OTC                             148.7   148.4   0.2%     151.4   -1.8%
Health and Beauty Products       47.6    26.8   78.0%     43.9   8.5%
Hospitals + Vaccines             21.0    27.6   -24.1%    22.7   -7.6%

Total                           778.8   766.0   1.7%     832.3   -6.4%




                                                                          5   5
Market Share Evolution (%)



                          11.5    11.7
                                             10.9*                    10.9*   10.4*
                                                         10.2*
       9.6                                                                                    9.9*




      2006                2007    2008       2009        2010         1Q10    4Q10           1Q11

*Excluding the similar’s effect                                                 Source: IMS and Profarma




                                                                                                           6   6
Gross Profit and Revenues from Services to Suppliers
                 (R$ million and as % Net Revenues)




   10.4%
                               10.1%
                                                        9.6%




    20.0                        28.4
                                                         24.0




    46.5                        41.7                     39.1




    1Q10                       4Q10                     1Q11

Gross Profit   Revenues from Services to Suppliers    Gross Profit Margin (%)




                                                                                7   7
Operating Expenses
       (R$ million and as % Net Revenues)



7.5%                7.4%                    7.7%



                     51.5                   50.7
48.1




1Q10                4Q10                    1Q11




                                                   8   8
Ebitda and Ebitda Margin
       (R$ million and as % Net Revenues)




2.8%                  2.7%
                                            1.7%



17.9                  18.6

                                            10.9




1Q10                  4Q10                  1Q11




                                                   9   9
Net Financial Expenses
       (R$ million and as % Net Revenues)




                     0.9%                   1.1%
0.8%




                                            7.2
                      6.0
5.4




1Q10                 4Q10                   1Q11




                                                   10 10
Net Profit
       (R$ million and as % Net Revenues)




1.2%                 1.5%
                                            0.3%



                     10.5


7.8




                                            2.2




1Q10                 4Q10                   1Q11




                                                   11 11
CASH FLOW

(R$ Million)                                            1Q11      1Q10    Chg. %    4Q10     Chg. %

Cash Flow Generated / (Used) in Operating Activities    (80.2)   (43.2)   -85.5%    (21.3)   -276.6%
  Internal Cash Generation                              10.4     18.6     -43.9%    22.2     -53.2%
  Operating Assets Variation                            (90.6)   (61.8)   -46.6%    (43.5)   -108.2%
     Trade Accounts Receivable                          22.9     (1.8)       -      (16.4)      -
     Inventories                                        (30.8)   (18.7)   -64.5%    (64.7)   52.5%
     Suppliers                                          (74.7)   (38.9)   -92.3%    68.5        -
     Other Items                                        (8.1)    (2.5)    -227.7%   (30.9)   73.9%

Cash Flow (Used) in Investing Activities                (1.3)    (1.5)    14.0%     (3.3)    61.9%

Cash Flow Generated / (Used) by Financing Activities    81.1     69.2     17.2%     (15.5)      -

Net Increase / (Decrease) in Cash                       (0.4)    24.5        -      (40.1)   99.1%




                                                                                                       12 12
Cycle IFRS Basis

                                             1Q10 4Q10 1Q11
         Cash Cycle (Days) *                     64.9   49.0   64.5

  Accounts Receivable (1)                        43.4   43.6   43.9
  Inventories (2)                                59.9   52.0   59.3
  Accounts Payable (3)                           38.4   46.6   38.7

* Average

(1)   Average of Gross Revenues in the Quarter
(2)   Average of COGS in the Quarter
(3)   Average of COGS in the Quarter




                                                                      13 13
Indebtedness: Net Debt and Net Debt / Ebitda*
                                        (R$ million)




                                                                2.7x
                     1.5x                  1.4x



                                                               194.8
                    167.3


                                          108.7




                    1Q10                  4Q10                 1Q11

* Ebitda = Accumulated last 12 months




                                                                       14 14
Capex
       (R$ million and % as Net Revenues)




                     0.5%
0.2%                                        0.2%




                      3.5


1.5                                         1.3




1Q10                 4Q10                   1Q11




                                                   15 15
Operating Indicators

                Service Level                                         Logistics E.P.M.
        (Units served/ Units requested)                               (Errors per Million)



92.3%                                                         210.0

                                                                          170.0
                                          89.5%
                                                                                             144.0
                    88.1%




1Q10                4Q10                  1Q11                1Q10         4Q10              1Q11




                                                                                                     16 16
Profarma vs Ibovespa - % (mar/10 - mar/11)
120




110




100                                                                                                                          97




90


                                                                                                                             82
80




70
  Mar-10   Apr-10   May-10   Jun-10   Jul-10   Aug-10      Sep-10   Oct-10      Nov-10   Dec-10   Jan-11   Feb-11   Mar-11

                                                        Ibovespa     Profarma




                                                                                                                                  17 17
Analyst Coverage

Company          Analyst                              Telephone           E-mail

                 Javier Martinez de Olcoz Cerdan      (1 212) 761-4542    javier.martinez.olcoz@morganstanley.com
Morgan Stanley
                 Clarissa Berman                      (55 11) 3048-6214   clarissa.berman@morganstanley.com


Merrill Lynch    Alexandre Pizano                     (55 11) 2188-4024   alexandre.pizano@baml.com


Credit Suisse    Marcel Moraes                        (55 11) 3841-6302   marcel.moraes@credit-suisse.com


                 Juliana Rozenbaum                    (55 11) 3073-3035   juliana.rozenbaum@itausecurities.com
Itaú BBA
                 Marcio Osako                         (55 11) 3073-3040   marcio.osako@itausecurities.com


Banco Fator      Iago Whately                         (55 11) 3049-9480   iwhately@bancofator.com.br


Raymond James    Guilherme Assis                      (55 11) 3513-8706   guilherme.assis@raymondjames.com


BTG Pactual      João Carlos dos Santos               (55 11) 3383-2384   joaocarlos.santos@btgpactual.com




                                                                                                                    18 18
19

Mais conteúdo relacionado

Mais procurados

Earnings Release 1 Q07
Earnings Release 1 Q07Earnings Release 1 Q07
Earnings Release 1 Q07
Profarma
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Eng
profarma1
 
Profarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 EngProfarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 Eng
profarma1
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
Profarma
 
100804 apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
100804   apresentação de resultados 2 t10-inglês_sem script [modo de compatib...100804   apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
100804 apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
Multiplus
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
Profarma
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
Profarma
 
Pfizer Quarterly Corporate Performance - Fourth Quarter 2007
Pfizer Quarterly Corporate Performance - Fourth Quarter 2007Pfizer Quarterly Corporate Performance - Fourth Quarter 2007
Pfizer Quarterly Corporate Performance - Fourth Quarter 2007
finance5
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 final
Profarma
 

Mais procurados (12)

Earnings Release 1 Q07
Earnings Release 1 Q07Earnings Release 1 Q07
Earnings Release 1 Q07
 
Profarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 EngProfarma Apresentacao 3 Q08 20081105 Eng
Profarma Apresentacao 3 Q08 20081105 Eng
 
Apresentacao Call Result 1 T08 Eng Final
Apresentacao Call Result 1 T08 Eng FinalApresentacao Call Result 1 T08 Eng Final
Apresentacao Call Result 1 T08 Eng Final
 
Profarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 EngProfarma Apr2 T08 20080729 Eng
Profarma Apr2 T08 20080729 Eng
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
 
100804 apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
100804   apresentação de resultados 2 t10-inglês_sem script [modo de compatib...100804   apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
100804 apresentação de resultados 2 t10-inglês_sem script [modo de compatib...
 
Investors meeting 1 q08 results
Investors meeting   1 q08 resultsInvestors meeting   1 q08 results
Investors meeting 1 q08 results
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Investors' meeting 2 q08 results
Investors' meeting   2 q08 resultsInvestors' meeting   2 q08 results
Investors' meeting 2 q08 results
 
Pfizer Quarterly Corporate Performance - Fourth Quarter 2007
Pfizer Quarterly Corporate Performance - Fourth Quarter 2007Pfizer Quarterly Corporate Performance - Fourth Quarter 2007
Pfizer Quarterly Corporate Performance - Fourth Quarter 2007
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 final
 

Semelhante a Profarma apresentacao 1_q11

Profarma 4 q11
Profarma 4 q11Profarma 4 q11
Profarma 4 q11
Profarma
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
Profarma
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
Profarma
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
Profarma
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
Profarma
 
Earnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationEarnings Release 1Q07 Presentation
Earnings Release 1Q07 Presentation
Profarma
 
arnings Release 2Q07 Presentation
arnings Release 2Q07 Presentationarnings Release 2Q07 Presentation
arnings Release 2Q07 Presentation
Profarma
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 Presentation
Profarma
 
Earnings Release 3 Q07
Earnings Release 3 Q07Earnings Release 3 Q07
Earnings Release 3 Q07
Profarma
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12
Profarma
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
Profarma
 
Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 Presentation
Profarma
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07
Profarma
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
Profarma
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results
Embraer RI
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 Presentation
Profarma
 
Earnings Release 1 Q09
Earnings Release 1 Q09Earnings Release 1 Q09
Earnings Release 1 Q09
Profarma
 

Semelhante a Profarma apresentacao 1_q11 (20)

Profarma 4 q11
Profarma 4 q11Profarma 4 q11
Profarma 4 q11
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Earnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationEarnings Release 1Q07 Presentation
Earnings Release 1Q07 Presentation
 
arnings Release 2Q07 Presentation
arnings Release 2Q07 Presentationarnings Release 2Q07 Presentation
arnings Release 2Q07 Presentation
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 Presentation
 
Earnings Release 3 Q07
Earnings Release 3 Q07Earnings Release 3 Q07
Earnings Release 3 Q07
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12
 
Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
 
Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 Presentation
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 Presentation
 
Earnings Release 1 Q09
Earnings Release 1 Q09Earnings Release 1 Q09
Earnings Release 1 Q09
 

Mais de Profarma

Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016
Profarma
 

Mais de Profarma (20)

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 Presentation
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings release
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain Acquisition
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16
 
Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vf
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejo
 
1 q16
1 q161 q16
1 q16
 
4 t15
4 t154 t15
4 t15
 

Profarma apresentacao 1_q11

  • 1. 1
  • 2. 1Q11 Earnings Release May, 11th, 2011 2
  • 3. Highlights in the Period • In May 2011, Profarma celebrates its 50th Anniversary. The Company’s result-oriented culture, coupled with a long-term vision based on everyday practical and objective initiatives, will be crucial to continue consolidating its position in the pharmaceutical distribution industry in Brazil; • A rise of 1.7% in the consolidated gross revenues when compared to the same period in the previous year, totaling R$ 778.8 million; • Highlight for the Health and Beauty category, which showed growing sales for the fifth consecutive quarter, and an outstanding increase of 78.0% in comparison with the same period in the previous year; • A drop of 31.4% in the EPM (Errors Per Million of shipped units), which changed from 210.0 recorded in the 1Q10 to 144.0 in the 1Q11; • The annual prices increase occurred in March 31, 2011 was 4.6%, in line with the inflation accrued over the last 12 months. This is the second higher price increase over the last five years. 3 3
  • 4. Gross Revenues Evolution (R$ Million) 832.3 766.0 778.8 1Q10 4Q10 1Q11 4 4
  • 5. Gross Revenues Breakdown (R$ Million) 1Q11 1Q10 Chg. % 4Q10 Chg. % Branded 507.1 511.7 -0.9% 554.6 -8.6% Generic 54.5 51.6 5.6% 59.6 -8.7% OTC 148.7 148.4 0.2% 151.4 -1.8% Health and Beauty Products 47.6 26.8 78.0% 43.9 8.5% Hospitals + Vaccines 21.0 27.6 -24.1% 22.7 -7.6% Total 778.8 766.0 1.7% 832.3 -6.4% 5 5
  • 6. Market Share Evolution (%) 11.5 11.7 10.9* 10.9* 10.4* 10.2* 9.6 9.9* 2006 2007 2008 2009 2010 1Q10 4Q10 1Q11 *Excluding the similar’s effect Source: IMS and Profarma 6 6
  • 7. Gross Profit and Revenues from Services to Suppliers (R$ million and as % Net Revenues) 10.4% 10.1% 9.6% 20.0 28.4 24.0 46.5 41.7 39.1 1Q10 4Q10 1Q11 Gross Profit Revenues from Services to Suppliers Gross Profit Margin (%) 7 7
  • 8. Operating Expenses (R$ million and as % Net Revenues) 7.5% 7.4% 7.7% 51.5 50.7 48.1 1Q10 4Q10 1Q11 8 8
  • 9. Ebitda and Ebitda Margin (R$ million and as % Net Revenues) 2.8% 2.7% 1.7% 17.9 18.6 10.9 1Q10 4Q10 1Q11 9 9
  • 10. Net Financial Expenses (R$ million and as % Net Revenues) 0.9% 1.1% 0.8% 7.2 6.0 5.4 1Q10 4Q10 1Q11 10 10
  • 11. Net Profit (R$ million and as % Net Revenues) 1.2% 1.5% 0.3% 10.5 7.8 2.2 1Q10 4Q10 1Q11 11 11
  • 12. CASH FLOW (R$ Million) 1Q11 1Q10 Chg. % 4Q10 Chg. % Cash Flow Generated / (Used) in Operating Activities (80.2) (43.2) -85.5% (21.3) -276.6% Internal Cash Generation 10.4 18.6 -43.9% 22.2 -53.2% Operating Assets Variation (90.6) (61.8) -46.6% (43.5) -108.2% Trade Accounts Receivable 22.9 (1.8) - (16.4) - Inventories (30.8) (18.7) -64.5% (64.7) 52.5% Suppliers (74.7) (38.9) -92.3% 68.5 - Other Items (8.1) (2.5) -227.7% (30.9) 73.9% Cash Flow (Used) in Investing Activities (1.3) (1.5) 14.0% (3.3) 61.9% Cash Flow Generated / (Used) by Financing Activities 81.1 69.2 17.2% (15.5) - Net Increase / (Decrease) in Cash (0.4) 24.5 - (40.1) 99.1% 12 12
  • 13. Cycle IFRS Basis 1Q10 4Q10 1Q11 Cash Cycle (Days) * 64.9 49.0 64.5 Accounts Receivable (1) 43.4 43.6 43.9 Inventories (2) 59.9 52.0 59.3 Accounts Payable (3) 38.4 46.6 38.7 * Average (1) Average of Gross Revenues in the Quarter (2) Average of COGS in the Quarter (3) Average of COGS in the Quarter 13 13
  • 14. Indebtedness: Net Debt and Net Debt / Ebitda* (R$ million) 2.7x 1.5x 1.4x 194.8 167.3 108.7 1Q10 4Q10 1Q11 * Ebitda = Accumulated last 12 months 14 14
  • 15. Capex (R$ million and % as Net Revenues) 0.5% 0.2% 0.2% 3.5 1.5 1.3 1Q10 4Q10 1Q11 15 15
  • 16. Operating Indicators Service Level Logistics E.P.M. (Units served/ Units requested) (Errors per Million) 92.3% 210.0 170.0 89.5% 144.0 88.1% 1Q10 4Q10 1Q11 1Q10 4Q10 1Q11 16 16
  • 17. Profarma vs Ibovespa - % (mar/10 - mar/11) 120 110 100 97 90 82 80 70 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Ibovespa Profarma 17 17
  • 18. Analyst Coverage Company Analyst Telephone E-mail Javier Martinez de Olcoz Cerdan (1 212) 761-4542 javier.martinez.olcoz@morganstanley.com Morgan Stanley Clarissa Berman (55 11) 3048-6214 clarissa.berman@morganstanley.com Merrill Lynch Alexandre Pizano (55 11) 2188-4024 alexandre.pizano@baml.com Credit Suisse Marcel Moraes (55 11) 3841-6302 marcel.moraes@credit-suisse.com Juliana Rozenbaum (55 11) 3073-3035 juliana.rozenbaum@itausecurities.com Itaú BBA Marcio Osako (55 11) 3073-3040 marcio.osako@itausecurities.com Banco Fator Iago Whately (55 11) 3049-9480 iwhately@bancofator.com.br Raymond James Guilherme Assis (55 11) 3513-8706 guilherme.assis@raymondjames.com BTG Pactual João Carlos dos Santos (55 11) 3383-2384 joaocarlos.santos@btgpactual.com 18 18
  • 19. 19